WallStreetZenWallStreetZen

NASDAQ: CRBP
Corbus Pharmaceuticals Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRBP

Based on 4 analysts offering 12 month price targets for Corbus Pharmaceuticals Holdings Inc

Min Forecast
$38.00+299.58%
Avg Forecast
$47.00+394.22%
Max Forecast
$57.00+499.37%

Should I buy or sell CRBP stock?

Based on 4 analysts offering ratings for Corbus Pharmaceuticals Holdings Inc.

Buy
Strong Buy
0 analysts 0%
Buy
4 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRBP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CRBP as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CRBP stock forecasts and price targets.

CRBP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-10
lockedlocked$00.00+00.00%2025-11-13
lockedlocked$00.00+00.00%2025-10-20
lockedlocked$00.00+00.00%2025-10-20

1 of 1

Forecast return on equity

Is CRBP forecast to generate an efficient return?

Company
-66.71%
Industry
66.44%
Market
180.65%
CRBP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRBP forecast to generate an efficient return on assets?

Company
-58.5%
Industry
31.83%
CRBP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRBP earnings per share forecast

What is CRBP's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$5.54
Avg 2 year Forecast
-$5.60
Avg 3 year Forecast
-$6.45

CRBP revenue forecast

What is CRBP's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$3.4M
Avg 2 year Forecast
$6.8M
Avg 3 year Forecast
$26.4M

CRBP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRBP$9.51$47.00+394.22%Buy
HRTX$0.90$6.00+568.90%Buy
SGMT$5.14$26.00+405.84%Strong Buy
KLRS$8.81$19.50+121.34%Strong Buy
ELDN$2.74$8.00+191.97%Strong Buy
View Top Biotech Stocks

Corbus Pharmaceuticals Holdings Stock Forecast FAQ

Is Corbus Pharmaceuticals Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CRBP) stock is to Buy CRBP stock.

Out of 4 analysts, 0 (0%) are recommending CRBP as a Strong Buy, 4 (100%) are recommending CRBP as a Buy, 0 (0%) are recommending CRBP as a Hold, 0 (0%) are recommending CRBP as a Sell, and 0 (0%) are recommending CRBP as a Strong Sell.

If you're new to stock investing, here's how to buy Corbus Pharmaceuticals Holdings stock.

What is CRBP's earnings growth forecast for 2026-2028?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.26%.

Corbus Pharmaceuticals Holdings's earnings in 2026 is -$78,537,000.On average, 11 Wall Street analysts forecast CRBP's earnings for 2026 to be -$98,190,838, with the lowest CRBP earnings forecast at -$126,539,029, and the highest CRBP earnings forecast at -$72,630,820. On average, 11 Wall Street analysts forecast CRBP's earnings for 2027 to be -$99,276,310, with the lowest CRBP earnings forecast at -$157,652,334, and the highest CRBP earnings forecast at -$49,724,177.

In 2028, CRBP is forecast to generate -$114,389,551 in earnings, with the lowest earnings forecast at -$150,352,005 and the highest earnings forecast at -$67,416,300.

What is CRBP's revenue growth forecast for 2026-2028?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.

Corbus Pharmaceuticals Holdings's revenue in 2026 is $0.On average, 10 Wall Street analysts forecast CRBP's revenue for 2026 to be $60,303,978, with the lowest CRBP revenue forecast at $0, and the highest CRBP revenue forecast at $372,465,744. On average, 10 Wall Street analysts forecast CRBP's revenue for 2027 to be $120,004,915, with the lowest CRBP revenue forecast at $0, and the highest CRBP revenue forecast at $372,465,744.

In 2028, CRBP is forecast to generate $468,827,953 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,910,749,267.

What is CRBP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CRBP) forecast ROA is -58.5%, which is lower than the forecast US Biotechnology industry average of 31.83%.

What is CRBP's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CRBP price target, the average CRBP price target is $47.00, with the highest CRBP stock price forecast at $57.00 and the lowest CRBP stock price forecast at $38.00.

On average, Wall Street analysts predict that Corbus Pharmaceuticals Holdings's share price could reach $47.00 by Mar 10, 2027. The average Corbus Pharmaceuticals Holdings stock price prediction forecasts a potential upside of 394.22% from the current CRBP share price of $9.51.

What is CRBP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's current Earnings Per Share (EPS) is -$5.90. On average, analysts forecast that CRBP's EPS will be -$5.54 for 2026, with the lowest EPS forecast at -$7.13, and the highest EPS forecast at -$4.10. On average, analysts forecast that CRBP's EPS will be -$5.60 for 2027, with the lowest EPS forecast at -$8.89, and the highest EPS forecast at -$2.80. In 2028, CRBP's EPS is forecast to hit -$6.45 (min: -$8.48, max: -$3.80).

What is CRBP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CRBP) forecast ROE is -66.71%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.